scioDiscover - Protein Expression Analysis

Protein expression profiling with protein arrays

Our scioDiscover service enables high-content, immuno-based protein profiling of various biological samples leading to a comprehensive overview of proteomic changes. Key pathways in various diseases such as cancer, neurological disorders and organ failure are covered. The technology was successfully applied in a variety of biomedical studies and to discover new biomarker signatures. Within the analysis, 1,300 proteins are analysed in parallel. The scioDiscover protein array based service enables fast and targeted research while still offering a broad overview of potential changes on the protein level in your samples.

 

Features

  • Major pathways, secreted proteins, cell surface and inflammatory markers are covered
  • 1,300 proteins are profiled
  • Broad spectrum of indications covered such as oncology and organ failure
  • Robust dual-colour study design
  • Including full data analysis and study report
  • Studies possible in human, murine and rat samples*

 

 Array
 content
    Protein
 profiling
    Biomarker
 Discovery
     Target
 Discovery
     Contact
 us

 

 

Applications

  • Protein expression level analysis
  • Signalling Pathway Profiling
  • Immunsystem activation marker profiling
  • Transcription factor analysis 
  • Cancer pathway screening
  • Cell surface marker profiling
  • Profiling of apoptotic processes/ apoptosis pathway analysis 

 

  • Disease mechanism profiling
  • Pathway activation in stem cells 
  • Analysis of organ damage/failure models 
  • Response of cells and tissue models to oxidative stress analysis
  • Profiling proteomic changes for various cell culture conditions

 

  • Molecular initiate event analysis
  • Compound mode-of-action analysis
  • Prediction markers for toxicological effects 

 

 

  • CD cell surface molecule expression in immune cells  

 

 

 

 

Advantages

  • high-content protein profiling of 1,300 proteins 
  • broad coverage of:
    • signalling pathway proteins
    • transcription factors
    • apoptosis marker
    • markers for oxidative stress
    • cell surface markers
    • cytokines & chemokines

 

  • minimal sample requirements
  • native matrixes (non-fractionated / non-depleted)
  • sensitivity as ELISA or better

 

  • fully immuno-based assay

 

  • reliable dual-colour study design
  • technical replication ( 4 replicates for each antibody )
  • high reproducibility ( CV < 10% )

 

  • experienced partners with more than ten years of experience in conducting biomedical antibody array studies

 

 

Save time, costs and valuable sample

 

 

 

Reference Customers:

  • Prof. Dr. Faikah Güler, Molecular mechanisms of transplant dysfunction, Medical School Hanover, Hanover, Germany
  • Julian Kamhieh-Milz, Research Center ImmunoSciences, Charité, Berlin, Germany
  • Prof. Jose L. Peiró, Cincinnati Fetal Center Director, Cincinnati Children's Hospital Medical Center (CCHMC), Cincinnati, USA
 

Case studies:

Bladder Cancer

Acute Kidney Injury


 

Which sample types can be analysed ?

With the scioDiscover service a variety of samples can be analysed:

  • plasma / serum
  • fresh frozen tissue samples
  • cellular content
  • cell culture supernatant
  • cerebrospinal fluid
  • additional sample types on request
  • studies possible in samples from human, mouse or rat*

* Antibody array is designed to target human proteins. Due to a high sequence homology of vast majority of proteins it was often successfully applied to study murine, rat and ovine models as well  [Thorenz A. et al. (2018), Peiro J. et al. (2018), Reichman H. et al. (2019), Raquel F. et al. (2020)].

Sample-to-result serviceAntibody microarray workflow

Within our analysis service, we will not only carry out the microarray experiments but also support you with a suggestion for an appropriate microarray study design as well as with the sample selection process in order to address your scientific question in the optimal way. Within 3-4 weeks after receipt of your samples you will receive a customised study report including a statistical analysis.

Our analysis service includes:

  • definition of an appropriate study design
  • sample preparation
  • protein extraction
  • protein concentration measurements
  • protein quality control
  • sample labelling
  • sample purification
  • incubation of the samples on antibody microarrays
  • microarray scanning
  • raw data acquisition
  • data normalisation
  • data analysis including cluster analysis
  • statistical testing for differentially abundant proteins
  • comprehensive study report

 

Our service portfolio

scioPhospho: protein profiling and phosphorylation status

scioPhospho: protein profiling and phosphorylation status

scioPhospho combines the advantages of a robust and cost-efficient protein expression profiling using scioDiscover with information on phosphorylation status. This combination provides a comprehensive overview on signalling events and pathway activity regulation. Features 1,300 highly relevant proteins are profiled in a single assay Phosphorylation status combined with protein expression levels…
Read more
scioDiscover - Protein Profiling on expression level

scioDiscover - Protein Profiling on expression level

Knowledge about protein expression levels is of utmost importance to predict toxic effects, estimate adverse effects of drug candidates and to identify new drug targets. Sciomics has a highly optimised…
scioCD - Cell surface marker and Cytokine profiling

scioCD - Cell surface marker and Cytokine profiling

  Characterise a certain cell type?   Cell composition in a certain tissue sample?   In-depth profiling of CD-marker expression?   Increase your throughput at high sensitivity levels? You aim…
scioUbi

scioUbi

Protein & ubiquitination profiling scioUbi is a high-content protein expression and ubiquitination level analysis. With scioUbi you can analyse up to 1,000 proteins in a single assay.   Features Screen…
scioCyto : Cytokine profiling

scioCyto : Cytokine profiling

scioCyto : Cytokine profiling scioCyto is a high-content analysis service for multiplex cytokine and chemokine profiling on protein level. A great variety of samples such as plasma, tissue, cells or…

COVID-19 related activities and services

covid 19 portfolio web

News

New article | Anti-cancer activity and mechanism of action of metformin in endometrial cancer cells

| March 2021 | Scientists at Heidelberg University Hospital characterized the protein profile response of an endometrial cell line to Metformin treatment and hyperinsulinemia  with our scioDiscover platform:

"The presented data helps identify potential targets affected by metformin treatment in EC and allows for a better understanding of the mechanism of action of the biguanide drug’s anti-cancer activity.

With the presented data, we contribute to a better understanding of the anti-cancer activity of metformin as well as its underlying mechanism of action in EC cells."

Lange, C. et al. (2021) ‘Changes in protein expression due to metformin treatment and hyperinsulinemia in a human endometrial cancer cell line’, PLoS ONE 16(3):e0248103. https://doi.org/10.1371/journal.pone.0248103 

New article | Selective elimination of immunosuppressive T cells in patients with multiple myeloma

| Feb 2021 | Scientists at Heidelberg University Hospital used our scioCD  platform to profile CD8+SLAMF7+ cell cultures:

"High throughput screening of 351 different cytokines and immune proteins in the supernatants of the T cells cultures revealed strong upregulation of IL-6, IL-8, both vital survival factors for myeloma cells, and CXCL5, a chemokine that could enhance the frequency of CD4 Treg, in the cultures containing CD8+SLAMF7+ cells. IL-2 and IL-5 were upregulated in the control cultures without CD8+SLAMF7+ T cells, highlighting a more activated state in the control group and suggestion IL-6 and IL-8 as potential effector cytokines for the suppressive CD8+SLAMF7+ T cells."

Awwad, M. H. S. et al. (2021) ‘Selective elimination of immunosuppressive T cells in patients with multiple myeloma’, Leukemia, pp. 1–14. doi: 10.1038/s41375-021-01172-x.

 

New article | Analysis of the Differential Gene and Protein Expression Profiles of Corneal Epithelial Cells Stimulated with Alternating Current Electric Fields

| Feb 2021 | Scientists at Rostock University Medical Center used our scioCD  platform to Corneal Epithelial Cells stimulated with Alternating Current Electric Fields:

"Analysis of the protein array data revealed that the treatment of cells with AC EFs altered the expression of various protein products ... revealed activation of various diverse cellular signaling pathways in which TNF, MAPK, IL17, and PI3K-Akt signaling pathways were significantly impacted ..."

B. S. Kowtharapu et. al., „Analysis of the Differential Gene and Protein Expression Profiles of Corneal Epithelial Cells Stimulated with Alternating Current Electric Fields“, Genes, Bd. 12, Nr. 2, Art. Nr. 2, Feb. 2021, doi: 10.3390/genes12020299.

 

New article | BET-Inhibitor I-BET762 and PARP-Inhibitor Talazoparib Synergy in Small Cell Lung Cancer Cells

| Dec 2020 | Scientists at University of Sassari used our scioPhospho  platform to to analyse the synergy of BET and PARP inhibition in Small Cell Lung Cancer Cells:

"Among the I-BET762-associated and combination-associated differentially expressed proteins, 150 were common to both treatment conditions. ... Ranking I-BET762-associated and combination-associated DEPs by their differential expression revealed CHEK2 and PTEN to be among the top-downregulated proteins, whose deficiencies have been associated with HR defects and increased PARPi sensitivity. "

Fiorentino, F. P. et al. (2020) ‘BET-Inhibitor I-BET762 and PARP-Inhibitor Talazoparib Synergy in Small Cell Lung Cancer Cells’, International Journal of Molecular Sciences, 21(24). doi: 10.3390/ijms21249595.

 

New article | Activated Eosinophils Exert Antitumorigenic Activities in Colorectal Cancer

| Jan 2019 | In the article, scientists at Tel Aviv University used our scioDiscover platform to analyse tumor-associated eosinophils in colorectal cancer. The full article is published in Cancer Immunology Research.

 

Testimonials

Dr. Joachim Lupberger 

Institute for Viral and Liver Disease, Inserm U1110, University of Strasbourg, LabEx HepSYS, Strasbourg, France

"Our lab is focusing on the identification of minimal-invasive biomarkers for liver disease progression. A challenge of our humanized animal models for liver disease is the low volume of blood samples available, which did not pose any problem for the analysis. I was pleased by the prompt, friendly, and uncomplicated contact and was impressed by the results and the thorough report we received. The overall quality was excellent, which made us to continue using the service of Sciomics for follow-up projects analyzing patient material."

Product: scioPhospho

 

 Prof. Dr. Andreas Weigert 

Goethe-University Frankfurt, Faculty of Medicine, Institute of Biochemistry I, Frankfurt, Germany

"We were under considerable time pressure to gain comprehensive information about cytokine/chemokine levels in a mouse model of self-resolving inflammation. To add to our misery, we had only a small number of biological replicates to run the analyses. Thankfully, the team at Sciomics were able to come to our rescue by providing a very prompt analysis, without neglecting to properly communicate the procedure, potential caveats and other details. The whole process was a very satisfying experience, rather like working with committed colleagues than with a company, and we got great data out of the project. I do happily recommend working with Sciomics for targeted proteomics analyses."

Product: scioCD

 

Tweets

  • 4 days ago

    Happy to have supported Prof. Wagner's, Uni Heidelberg, research project. Our broad spectrum array scioDiscover ena… https://t.co/wTTVFw3cp5

  • 12 days ago

    A fruitful collaboration with Francesco P. Fiorentino @fistaral et al. got published in Int J Mol Sci: BET-Inhibito… https://t.co/cQvVu3sSxi

  • 22 days ago

    RT @car_endo: BioEndoCar @car_endo is delighted to announce that the #targeted #metabolomics measurements were finished. We obtained the co…

  • 33 days ago

    Tune into our CEO Dr. Christoph Schröder’s @ChristophSch78 exciting talk: “Prediction of severe COVID-19 disease –… https://t.co/FrAB76Rij7

  • 47 days ago

    Join us at this year's BIO Digital virtual conference and learn how we can push your research forward with our prot… https://t.co/8eKhFB8Hmm